Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;44(9):1705-1711.
doi: 10.1111/jog.13716. Epub 2018 Jul 5.

Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol

Affiliations

Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol

Li-Ping Song et al. J Obstet Gynaecol Res. 2018 Sep.

Abstract

Aim: The aim of the present study was to investigate the safety and efficacy of low-dose mifepristone combined with self-administered misoprostol for termination of early pregnancy.

Methods: A total of 533 women seeking medical abortion in early pregnancy (≤49 days since the last menstrual period) were divided randomly into hospital- (H-Mis, 250) and self- (S-Mis, 283) administered misoprostol groups. Women in two groups took 100 mg of oral mifepristone in hospital followed by 200 μg of sublingual misoprostol 24 h later in hospital or home. The primary outcome parameter was complete abortion without surgical intervention. Secondary outcomes were uterine bleeding, return of regular menses, side effects and patient acceptability.

Results: High rates of complete abortion were observed for both the H-Mis group (243/250; 94.8%) and the S-Mis group (266/283; 94.0%). No significant differences in outcomes (complete abortion/failure rates) or side effects were observed between the two groups. General satisfaction rates were similar for the two groups (H-Mis, 231/250, 92.4%; S-Mis, 263/283, 92.9%; P > 0.05). Higher convenience of administration (H-Mis, 211/250, 84.4%; S-Mis, 270/283, 95.4%; P < 0.05) and privacy protection (H-Mis, 214/250, 85.6%; S-Mis, 267/283, 94.3%; P < 0.05) satisfaction rates were obtained for the S-Mis group than for the H-Mis group.

Conclusion: Self-administered sublingual misoprostol is as safe and effective as hospital-administered misoprostol following low-dose mifepristone to terminate early pregnancy (≤49 days of amenorrhoea) with fewer side effects.

Keywords: early medical abortion; low-dose; mifepristone and misoprostol; self-administration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram of study flow (Ms, indicates misoprostol.) Six hundred patients were enrolled in the group and were randomly grouped into the hospital and self‐administration groups and were treated with the same dose of drugs. Finally, data of 250 and 283 patients in the hospital and self‐administration groups were analyzed in our study.

References

    1. Gardner DK, Kelley RL. Impact of the IVF laboratory environment on human preimplantation embryo phenotype. J Dev Orig Health Dis 2017; 8: 418–435. - PubMed
    1. Khurana NK, Niemann H. Energy metabolism in preimplantation bovine embryos derived in vitro or in vivo . Biol Reprod 2000; 62: 847–856. - PubMed
    1. Li C, Chen D, Song L et al Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra‐early pregnancy: A dose‐ranging randomized controlled trial. Reprod Sci 2015; 22: 706–711. - PMC - PubMed
    1. Heikinheimo O, Leminen R, Suhonen S. Termination of early pregnancy using flexible, low‐dose mifepristone‐misoprostol regimens. Contraception 2007; 76: 456–460. - PubMed
    1. Anonymous . Lowering the doses of mifepristone and gameprost for early abortion: A randomised controlled trial World Health Organization Task Force on Post‐Ovulatory Methods for Fertility Regulation. BJOG 2001; 108: 738–742. - PubMed

MeSH terms